Login to Your Account

Tysabri Surprise Death Casts Grim Doubt On 'Blockbuster'

By Randall Osborne

Monday, March 7, 2005

In November, when their would-be blockbuster drug for multiple sclerosis won FDA approval based on a single year of data, Biogen Idec Inc. and Elan Corp. plc disclosed they had changed the name of the compound from Antegren (which had been used during its development) to the odd-looking and harder-to-pronounce Tysabri.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription